RxDoctor Payments Data

Larry Napolitano

Dermatology · Shelby, NCNPI 1487049656

Payments from drug & device makers

$2,573in general payments, 2019–2025

Across 119 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$179
  • Galderma Laboratories, L.p.$132
  • Almirall LLC$127
  • Sanofi$113
  • Novartis$95
  • plus $820 from 18 others

What the payments were for

  • Food & beverage$2,573100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,573 in reported general payments places this provider in the 50th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$903,960
Medicare patients
1,173
Services billed
14,948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa14$289,580
Dupixent PenDupilumab25$94,046
Taltz AutoinjectorIxekizumab13$90,364
Taltz SyringeIxekizumab11$78,964
OtezlaApremilast14$66,777
Metronidazole611$25,291
Ketoconazole766$13,774
Tacrolimus52$10,445
Ivermectin35$7,344
Clobetasol Propionate171$7,000
Triamcinolone Acetonide316$6,216
Clindamycin Phosphate116$4,711
Doxycycline Hyclate178$3,172
Minocycline Hcl83$2,216
Mometasone Furoate101$2,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$83$66,77714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Shelby

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →